News
Vast’s Lead Drug Candidate Receives Orphan Drug Designation for the Treatment of Respiratory Infection in Patients with Cystic Fibrosis
July 16, 2025
Read
Vast Granted Qualified Infectious Disease Product Designation from the FDA
March 25, 2025
Read
Vast Awarded $2 Million Grant to Combat Deadly Respiratory Bacteria
January 21, 2025
Read
Vast Therapeutics Selected to Present at the American Thoracic Society (ATS)2024 Respiratory Innovation Summit in San Diego, CA
April 17, 2024
Read
Vast Therapeutics Expands Leadership Team with Appointment of Dr. Paul Bruinenberg as Chief Medical Officer
March 7, 2024
Read
Vast Therapeutics Announces Publication of Potential New Treatment for Non-Tuberculosis Mycobacteria Infections
January 17, 2024
Read